{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:44:03Z","timestamp":1793724243223,"version":"4.6.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2022\/SKK06\/UM\/02\/5"],"award-info":[{"award-number":["FRGS\/1\/2022\/SKK06\/UM\/02\/5"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30652-8","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:54:00Z","timestamp":1770306840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Repurposing of natural products for spinocerebellar ataxia type 3 using integrated network pharmacology and in silico approaches"],"prefix":"10.1038","volume":"16","author":[{"given":"Miah","family":"Roney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Shahirah","family":"Mohd Hisam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Nazim","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Istiaque Hamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Wei","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Hui","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"30652_CR1","doi-asserted-by":"publisher","first-page":"104635","DOI":"10.1016\/j.nbd.2019.104635","volume":"134","author":"HS McLoughlin","year":"2020","unstructured":"McLoughlin, H. S., Moore, L. R. & Paulson, H. L. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol. Dis. 134, 104635. https:\/\/doi.org\/10.1016\/j.nbd.2019.104635 (2020).","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"30652_CR2","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1007\/s12311-023-01600-x","volume":"23","author":"F De Mattei","year":"2024","unstructured":"De Mattei, F. et al. Epidemiology of spinocerebellar ataxias in Europe. Cerebellum 23(3), 1176\u20131183. https:\/\/doi.org\/10.1007\/s12311-023-01600-x (2024).","journal-title":"Cerebellum"},{"key":"30652_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40673-020-00120-2","volume":"7","author":"N Mohamed Ibrahim","year":"2020","unstructured":"Mohamed Ibrahim, N. et al. Frequency of spinocerebellar ataxia type 1, 2, 3,6 and 7 and clinical profile of spinocerebellar ataxia type 3 in Malaysia. Cerebellum Ataxias 7, 11. https:\/\/doi.org\/10.1186\/s40673-020-00120-2 (2020).","journal-title":"Cerebellum Ataxias"},{"issue":"11","key":"30652_CR4","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1093\/nar\/gkad212","volume":"51","author":"E Hern\u00e1ndez-Carralero","year":"2023","unstructured":"Hern\u00e1ndez-Carralero, E. et al. ATXN3 controls DNA replication and transcription by regulating chromatin structure. Nucleic Acids Res. 51(11), 5396\u20135413. https:\/\/doi.org\/10.1093\/nar\/gkad212 (2023).","journal-title":"Nucleic Acids Res."},{"key":"30652_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.658339","volume":"14","author":"K Wiatr","year":"2021","unstructured":"Wiatr, K. et al. Broad influence of mutant ataxin-3 on the proteome of the adult brain, young neurons, and axons reveals central molecular processes and biomarkers in SCA3\/MJD using knock-in mouse model. Front. Mol. Neurosci. 14, 658339. https:\/\/doi.org\/10.3389\/fnmol.2021.658339 (2021).","journal-title":"Front. Mol. Neurosci."},{"key":"30652_CR6","doi-asserted-by":"publisher","unstructured":"Paulson, H. Chapter 9 - Repeat expansion diseases. In\u00a0Handbook of Clinical Neurology (eds\u00a0Geschwind, D.H. et al.)\u00a0147, 105\u2013123.\u00a0https:\/\/doi.org\/10.1016\/B978-0-444-63233-3.00009-9 (Elsevier, 2018).","DOI":"10.1016\/B978-0-444-63233-3.00009-9"},{"issue":"11","key":"30652_CR7","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.3390\/ijms23115933","volume":"23","author":"T Harmuth","year":"2022","unstructured":"Harmuth, T. et al. Mitochondrial dysfunction in spinocerebellar ataxia type 3 is linked to VDAC1 deubiquitination. Int. J. Mol. Sci.\u00a023(11), 5933.\u00a0https:\/\/doi.org\/10.3390\/ijms23115933 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"30652_CR8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s13311-019-00798-1","volume":"16","author":"JD Da Silva","year":"2019","unstructured":"Da Silva, J. D., Teixeira-Castro, A. & Maciel, P. From pathogenesis to novel therapeutics for spinocerebellar ataxia type 3: Evading potholes on the way to translation. Neurotherapeutics 16(4), 1009\u20131031. https:\/\/doi.org\/10.1007\/s13311-019-00798-1 (2019).","journal-title":"Neurotherapeutics"},{"key":"30652_CR9","doi-asserted-by":"publisher","first-page":"1460100","DOI":"10.3389\/fddsv.2024.1460100","volume":"4","author":"L Pinzi","year":"2024","unstructured":"Pinzi, L., Bisi, N. & Rastelli, G. How drug repurposing can advance drug discovery: Challenges and opportunities. Front. Drug Discov. 4, 1460100. https:\/\/doi.org\/10.3389\/fddsv.2024.1460100 (2024).","journal-title":"Front. Drug Discov."},{"key":"30652_CR10","doi-asserted-by":"publisher","first-page":"1201419","DOI":"10.3389\/fddsv.2023.1201419","volume":"3","author":"N Singh","year":"2023","unstructured":"Singh, N. et al. Drug discovery and development: Introduction to the general public and patient groups. Front. Drug Discov. 3, 1201419.\u00a0https:\/\/doi.org\/10.3389\/fddsv.2023.1201419 (2023).","journal-title":"Front. Drug Discov."},{"issue":"2","key":"30652_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1134\/S1068162023020139","volume":"49","author":"VS Kulkarni","year":"2023","unstructured":"Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A. & Murugesan, S. Drug repurposing: An effective tool in modern drug discovery. Russ. J. Bioorg. Chem. 49(2), 157\u2013166. https:\/\/doi.org\/10.1134\/S1068162023020139 (2023).","journal-title":"Russ. J. Bioorg. Chem."},{"key":"30652_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fonc.2017.00273","volume":"7","author":"JJ Hernandez","year":"2017","unstructured":"Hernandez, J. J. et al. Giving drugs a second chance: Overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front. Oncol. 7, 273. https:\/\/doi.org\/10.3389\/fonc.2017.00273 (2017).","journal-title":"Front. Oncol."},{"issue":"Part B","key":"30652_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.sajb.2022.05.028","volume":"151","author":"CB Aware","year":"2022","unstructured":"Aware, C. B. et al. Natural bioactive products as promising therapeutics: A review of natural product-based drug development. S. Afr. J. Bot.\u00a0151(Part B), 512\u2013528. https:\/\/doi.org\/10.1016\/j.sajb.2022.05.028 (2022).","journal-title":"S. Afr. J. Bot."},{"issue":"6","key":"30652_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3892\/br.2017.909","volume":"6","author":"S Mathur","year":"2017","unstructured":"Mathur, S. & Hoskins, C. Drug development: Lessons from nature. Biomed. Rep. 6(6), 612\u2013614. https:\/\/doi.org\/10.3892\/br.2017.909 (2017).","journal-title":"Biomed. Rep."},{"key":"30652_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.17179\/excli2018-1174","volume":"17","author":"S Mushtaq","year":"2018","unstructured":"Mushtaq, S., Abbasi, B. H., Uzair, B. & Abbasi, R. Natural products as reservoirs of novel therapeutic agents. EXCLI J. 17, 420\u2013451. https:\/\/doi.org\/10.17179\/excli2018-1174 (2018).","journal-title":"EXCLI J."},{"key":"30652_CR16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-024-51954-3","volume":"14","author":"M Naveed","year":"2024","unstructured":"Naveed, M. et al. The natural breakthrough: Pytochemicals as potent therapeutic agents against spinocerebellar ataxia type 3. Sci. Rep. 14, 1529. https:\/\/doi.org\/10.1038\/s41598-024-51954-3 (2024).","journal-title":"Sci. Rep."},{"issue":"6","key":"30652_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1934578X1300800608","volume":"8","author":"PA John","year":"2013","unstructured":"John, P. A., Wong, K. H., Naidu, M., Sabaratnam, V. & David, P. Combination effects of curcumin and aqueous extract of Lignosus rhinocerotis mycelium on neurite outgrowth stimulation activity in PC-12 cells. Nat. Prod. Commun. 8(6), 711\u2013714. https:\/\/doi.org\/10.1177\/1934578X1300800608 (2013).","journal-title":"Nat. Prod. Commun."},{"issue":"3","key":"30652_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1615\/IntJMedMushrooms.v19.i3.10","volume":"19","author":"KH Wong","year":"2017","unstructured":"Wong, K. H., Ng, C. C., Kanagasabapathy, G., Yow, Y. Y. & Sabaratnam, V. An overview of culinary and medicinal mushrooms in neurodegeneration and neurotrauma research. Int. J. Med. Mushrooms 19(3), 191\u2013202. https:\/\/doi.org\/10.1615\/IntJMedMushrooms.v19.i3.10 (2017).","journal-title":"Int. J. Med. Mushrooms"},{"key":"30652_CR19","doi-asserted-by":"publisher","first-page":"14945","DOI":"10.1038\/s41598-020-71966-z","volume":"10","author":"PS Chong","year":"2020","unstructured":"Chong, P. S. et al. Hericium erinaceus potentially rescues behavioural motor deficits through ERK-CREB-PSD95 neuroprotective mechanisms in rat model of 3-acetylpyridine-induced cerebellar ataxia. Sci. Rep. 10, 14945. https:\/\/doi.org\/10.1038\/s41598-020-71966-z (2020).","journal-title":"Sci. Rep."},{"issue":"Suppl. 1","key":"30652_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1590\/fst.09919","volume":"40","author":"SY Lew","year":"2020","unstructured":"Lew, S. Y., Yow, Y. Y., Lim, L. W. & Wong, K. H. Antioxidant-mediated protective role of Hericium erinaceus (Bull.: Fr.) Pers. against oxidative damage in fibroblasts from Friedreich\u2019s ataxia patient. Food. Sci. Technol.\u00a040\u00a0(Suppl.1), 264\u2013272.\u00a0https:\/\/doi.org\/10.1590\/fst.09919 (2020).","journal-title":"Food. Sci. Technol."},{"issue":"1","key":"30652_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13020-020-00414-x","volume":"16","author":"MWL Phang","year":"2021","unstructured":"Phang, M. W. L. et al. Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review. Chin. Med. 16(1), 15. https:\/\/doi.org\/10.1186\/s13020-020-00414-x (2021).","journal-title":"Chin. Med."},{"issue":"8","key":"30652_CR22","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.2174\/1570159X20666211217163540","volume":"20","author":"CK Woon","year":"2022","unstructured":"Woon, C. K. et al. Natural product-based nanomedicine: Recent advances and issues for the treatment of Alzheimer\u2019s disease. Curr. Neuropharmacol. 20(8), 1498\u20131518. https:\/\/doi.org\/10.2174\/1570159X20666211217163540 (2022).","journal-title":"Curr. Neuropharmacol."},{"issue":"6","key":"30652_CR23","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/ph15060764","volume":"15","author":"SY Lew","year":"2022","unstructured":"Lew, S. Y. et al. Discovery of therapeutics targeting oxidative stress in autosomal recessive cerebellar ataxia: A systematic review. Pharmaceuticals 15(6), 764. https:\/\/doi.org\/10.3390\/ph15060764 (2022).","journal-title":"Pharmaceuticals"},{"issue":"1","key":"30652_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/ph15010101","volume":"15","author":"KH Wong","year":"2022","unstructured":"Wong, K. H. et al. Discovering the potential of natural antioxidants in age-related macular degeneration: A review. Pharmaceuticals 15(1), 101. https:\/\/doi.org\/10.3390\/ph15010101 (2022).","journal-title":"Pharmaceuticals"},{"issue":"15","key":"30652_CR25","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3390\/cells11152284","volume":"11","author":"Yanshree","year":"2022","unstructured":"Yanshree, et al. The monkey head mushroom and memory enhancement in Alzheimer\u2019s disease. Cells 11(15), 2284. https:\/\/doi.org\/10.3390\/cells11152284 (2022).","journal-title":"Cells"},{"issue":"7","key":"30652_CR26","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.3390\/ijms24076089","volume":"24","author":"SC Chau","year":"2023","unstructured":"Chau, S. C. et al. Hericium erinaceus promotes anti-inflammatory effects and regulation of metabolites in an animal model of cerebellar ataxia. Int. J. Mol. Sci.\u00a024(7), 6089. https:\/\/doi.org\/10.3390\/ijms24076089 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"30652_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/antiox13030375","volume":"13","author":"NS Mohd Hisam","year":"2024","unstructured":"Mohd Hisam, N. S. & Wong, K. H. Oxidative stress in spinocerebellar ataxia type 3 and its attenuation by herbal remedies in traditional Chinese medicine: A systematic review. Antioxidants 13(3), 375. https:\/\/doi.org\/10.3390\/antiox13030375 (2024).","journal-title":"Antioxidants"},{"issue":"11","key":"30652_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1615\/IntJMedMushrooms.2025059734","volume":"27","author":"MWL Phang","year":"2025","unstructured":"Phang, M. W. L. et al. The tiger milk medicinal mushroom Lignosus rhinocerus (Agaricomycetes) mitigates oxidative damage in a cellular model mimicking Friedreich\u2019s ataxia. Int. J. Med. Mushrooms 27(11), 63\u201387. https:\/\/doi.org\/10.1615\/IntJMedMushrooms.2025059734 (2025).","journal-title":"Int. J. Med. Mushrooms"},{"issue":"5","key":"30652_CR29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/molecules25051154","volume":"25","author":"G Rastelli","year":"2020","unstructured":"Rastelli, G., Pellati, F., Pinzi, L. & Gamberini, M. C. Repositioning natural products in drug discovery. Molecules 25(5), 1154. https:\/\/doi.org\/10.3390\/molecules25051154 (2020).","journal-title":"Molecules"},{"issue":"7","key":"30652_CR30","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.drudis.2022.02.007","volume":"27","author":"B Huang","year":"2022","unstructured":"Huang, B. & Zhang, Y. Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives. Drug. Discov. Today 27(7), 1936\u20131944. https:\/\/doi.org\/10.1016\/j.drudis.2022.02.007 (2022).","journal-title":"Drug. Discov. Today"},{"issue":"7","key":"30652_CR31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/acn3.51370","volume":"8","author":"SM Brooker","year":"2021","unstructured":"Brooker, S. M., Edamakanti, C. R., Akasha, S. M., Kuo, S. H. & Opal, P. Spinocerebellar ataxia clinical trials: Opportunities and challenges. Ann. Clin. Transl. Neurol. 8(7), 1543\u20131556. https:\/\/doi.org\/10.1002\/acn3.51370 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"14","key":"30652_CR32","doi-asserted-by":"publisher","first-page":"16139","DOI":"10.1021\/acsomega.9b02328","volume":"4","author":"P Paudel","year":"2019","unstructured":"Paudel, P., Seong, S. H., Shrestha, S., Jung, H. A. & Choi, J. S. In vitro and in silico human monoamine oxidase inhibitory potential of anthraquinones, naphthopyrones, and naphthalenic lactones from Cassia obtusifolia Linn Seeds. ACS Omega 4(14), 16139\u201316152. https:\/\/doi.org\/10.1021\/acsomega.9b02328 (2019).","journal-title":"ACS Omega"},{"key":"30652_CR33","doi-asserted-by":"publisher","first-page":"100383","DOI":"10.1016\/j.chphi.2023.100383","volume":"7","author":"VN Kumar","year":"2023","unstructured":"Kumar, V. N. et al. In silico study of traditional Chinese medicinal compounds targeting Alzheimer\u2019s disease amyloid beta-peptide (1\u201342). Chem. Phys. Impact. 7, 100383. https:\/\/doi.org\/10.1016\/j.chphi.2023.100383 (2023).","journal-title":"Chem. Phys. Impact."},{"key":"30652_CR34","doi-asserted-by":"publisher","first-page":"17134","DOI":"10.1038\/s41598-025-98092-y","volume":"15","author":"MT Islam","year":"2025","unstructured":"Islam, M. T. et al. In silico screening of naturally derived dietary compounds as potential butyrylcholinesterase inhibitors for Alzheimer\u2019s disease treatment. Sci. Rep. 15, 17134. https:\/\/doi.org\/10.1038\/s41598-025-98092-y (2025).","journal-title":"Sci. Rep."},{"key":"30652_CR35","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fchem.2020.00612","volume":"8","author":"S Brogi","year":"2020","unstructured":"Brogi, S., Ramalho, T. C., Kuca, K., Medina-Franco, J. L. & Valko, M. Editorial: In silico methods for drug design and discovery. Front. Chem. 8, 612.\u00a0https:\/\/doi.org\/10.3389\/fchem.2020.00612 (2020).","journal-title":"Front. Chem."},{"issue":"4","key":"30652_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ipha.2024.01.010","volume":"2","author":"M Roney","year":"2024","unstructured":"Roney, M. & Mohd Aluwi, M. F. F. The importance of in-silico studies in drug discovery. Intell. Pharm. 2(4), 578\u2013579. https:\/\/doi.org\/10.1016\/j.ipha.2024.01.010 (2024).","journal-title":"Intell. Pharm."},{"issue":"18","key":"30652_CR37","doi-asserted-by":"publisher","first-page":"8831","DOI":"10.1080\/07391102.2022.2137699","volume":"41","author":"A Dhiman","year":"2023","unstructured":"Dhiman, A. & Purohit, R. Identification of potential mutational hotspots in serratiopeptidase to address its poor pH tolerance issue. J. Biomol. Struct. Dyn. 41(18), 8831\u20138843. https:\/\/doi.org\/10.1080\/07391102.2022.2137699 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"19","key":"30652_CR38","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.1080\/07391102.2022.2141895","volume":"41","author":"B Sharma","year":"2023","unstructured":"Sharma, B., Bhattacherjee, D., Zyryanov, G. V. & Purohit, R. An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders. J. Biomol. Struct. Dyn. 41(19), 9424\u20139436. https:\/\/doi.org\/10.1080\/07391102.2022.2141895 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"30652_CR39","doi-asserted-by":"publisher","first-page":"e30532","DOI":"10.1002\/jcb.30532","volume":"125","author":"A Gupta","year":"2024","unstructured":"Gupta, A. & Purohit, R. Identification of potent BRD4-BD1 inhibitors using classical and steered molecular dynamics based free energy analysis. J. Cell. Biochem. 125(3), e30532. https:\/\/doi.org\/10.1002\/jcb.30532 (2024).","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"30652_CR40","doi-asserted-by":"publisher","first-page":"103138","DOI":"10.1016\/j.jksus.2024.103138","volume":"36","author":"AK Singh","year":"2024","unstructured":"Singh, A. K. et al. A network pharmacology approach with experimental validation to discover protective mechanism of poly herbal extract on diabetes mellitus. J. King Saud Univ. Sci. 36(4), 103138. https:\/\/doi.org\/10.1016\/j.jksus.2024.103138 (2024).","journal-title":"J. King Saud Univ. Sci."},{"key":"30652_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.138580","volume":"287","author":"A Daroch","year":"2025","unstructured":"Daroch, A. & Purohit, R. MDbDMRP: A novel molecular descriptor-based computational model to identify drug-miRNA relationships. Int. J. Biol. Macromol. 287, 138580. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138580 (2025).","journal-title":"Int. J. Biol. Macromol."},{"key":"30652_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114180","volume":"276","author":"S Di","year":"2021","unstructured":"Di, S. et al. In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications. J. Ethnopharmacol. 276, 114180. https:\/\/doi.org\/10.1016\/j.jep.2021.114180 (2021).","journal-title":"J. Ethnopharmacol."},{"issue":"34","key":"30652_CR43","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.2174\/0929867323666160530144742","volume":"23","author":"M Hern\u00e1ndez-Rodr\u00edguez","year":"2016","unstructured":"Hern\u00e1ndez-Rodr\u00edguez, M., Rosales-Hern\u00e1ndez, M. C., Mendieta-Wejebe, J. E., Mart\u00ednez-Archundia, M. & Basurto, J. C. Current tools and methods in molecular dynamics (MD) simulations for drug design. Curr. Med. Chem. 23(34), 3909\u20133924. https:\/\/doi.org\/10.2174\/0929867323666160530144742 (2016).","journal-title":"Curr. Med. Chem."},{"key":"30652_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-0716-3441-7_7","volume":"2714","author":"S AlRawashdeh","year":"2024","unstructured":"AlRawashdeh, S. & Barakat, K. H. Applications of molecular dynamics simulations in drug discovery. Methods Mol. Biol. 2714, 127\u2013141. https:\/\/doi.org\/10.1007\/978-1-0716-3441-7_7 (2024).","journal-title":"Methods Mol. Biol."},{"key":"30652_CR45","doi-asserted-by":"publisher","first-page":"471659","DOI":"10.1155\/2013\/471659","volume":"2013","author":"KH Chang","year":"2013","unstructured":"Chang, K. H. et al. Aqueous extract of Paeonia lactiflora and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3. Evid. Based Complement. Altern. Med.\u00a02013, 471659.\u00a0https:\/\/doi.org\/10.1155\/2013\/471659 (2013).","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"30652_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neuropharm.2014.01.032","volume":"81","author":"KH Chang","year":"2014","unstructured":"Chang, K. H. et al. Aqueous extract of Gardenia jasminoides targeting oxidative stress to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3. Neuropharmacology 81, 166\u2013175. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.01.032 (2014).","journal-title":"Neuropharmacology"},{"key":"30652_CR47","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.freeradbiomed.2014.03.023","volume":"71","author":"CM Chen","year":"2014","unstructured":"Chen, C. M. et al. Aqueous extract of Glycyrrhiza inflata inhibits aggregation by upregulating PPARGC1A and NFE2L2-ARE pathways in cell models of spinocerebellar ataxia 3. Free Radic. Biol. Med. 71, 339\u2013350. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2014.03.023 (2014).","journal-title":"Free Radic. Biol. Med."},{"key":"30652_CR48","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2015.08.009","volume":"99","author":"AH Chou","year":"2015","unstructured":"Chou, A. H. et al. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse. Neuropharmacology 99, 308\u2013317. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.08.009 (2015).","journal-title":"Neuropharmacology"},{"issue":"1","key":"30652_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1142\/S0192415X19500046","volume":"47","author":"IC Chen","year":"2019","unstructured":"Chen, I. C. et al. Targeting ubiquitin proteasome pathway with traditional Chinese medicine for treatment of spinocerebellar ataxia type 3. Am. J. Chin. Med. 47(1), 63\u201395. https:\/\/doi.org\/10.1142\/S0192415X19500046 (2019).","journal-title":"Am. J. Chin. Med."},{"issue":"7","key":"30652_CR50","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/antiox11071389","volume":"11","author":"YL Wu","year":"2022","unstructured":"Wu, Y. L. et al. In vitro efficacy and molecular mechanism of curcumin analog in pathological regulation of spinocerebellar ataxia type 3. Antioxidants 11(7), 1389. https:\/\/doi.org\/10.3390\/antiox11071389 (2022).","journal-title":"Antioxidants"},{"key":"30652_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2022.12.005","volume":"195","author":"YL Wu","year":"2023","unstructured":"Wu, Y. L. et al. The protective effect of erinacine A-enriched Hericium erinaceus mycelium ethanol extract on oxidative stress-induced neurotoxicity in cell and Drosophila models of spinocerebellar ataxia type 3. Free Radic. Biol. Med. 195, 1\u201312. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.12.005 (2023).","journal-title":"Free Radic. Biol. Med."},{"key":"30652_CR52","doi-asserted-by":"publisher","first-page":"25979","DOI":"10.1038\/s41598-024-77763-2","volume":"14","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. Astragaloside IV reduces mutant ataxin-3 levels and supports mitochondrial function in spinocerebellar ataxia type 3. Sci. Rep. 14, 25979. https:\/\/doi.org\/10.1038\/s41598-024-77763-2 (2024).","journal-title":"Sci. Rep."},{"key":"30652_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.649606","volume":"12","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Network pharmacology-based analysis and experimental exploration of antidiabetic mechanisms of Gegen Qinlian decoction. Front. Pharmacol. 12, 649606. https:\/\/doi.org\/10.3389\/fphar.2021.649606 (2021).","journal-title":"Front. Pharmacol."},{"issue":"9","key":"30652_CR54","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/biology13090732","volume":"13","author":"N Sahu","year":"2024","unstructured":"Sahu, N. et al. Forecasting the pharmacological mechanisms of Plumbago zeylanica and Solanum xanthocarpum in diabetic retinopathy treatment: A network pharmacology, molecular docking, and molecular dynamics simulation study. Biology 13(9), 732. https:\/\/doi.org\/10.3390\/biology13090732 (2024).","journal-title":"Biology"},{"issue":"1","key":"30652_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"30652_CR56","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44(D1), D457\u2013D462. https:\/\/doi.org\/10.1093\/nar\/gkv1070 (2016).","journal-title":"Nucleic Acids Res."},{"key":"30652_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108378","volume":"116","author":"M Roney","year":"2025","unstructured":"Roney, M. et al. Repurposing of dipeptidyl peptidase FDA-approved drugs in Alzheimer\u2019s disease using network pharmacology and in-silico approaches. Comput. Biol. Chem. 116, 108378. https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108378 (2025).","journal-title":"Comput. Biol. Chem."},{"key":"30652_CR58","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1038\/s41598-021-83626-x","volume":"11","author":"FADM Opo","year":"2021","unstructured":"Opo, F. A. D. M. et al. Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Sci. Rep. 11, 4049. https:\/\/doi.org\/10.1038\/s41598-021-83626-x (2021).","journal-title":"Sci. Rep."},{"issue":"11","key":"30652_CR59","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1016\/j.bmcl.2008.04.034","volume":"18","author":"B Lippa","year":"2008","unstructured":"Lippa, B. et al. Synthesis and structure based optimization of novel Akt inhibitors. Bioorg. Med. Chem. Lett. 18(11), 3359\u20133363. https:\/\/doi.org\/10.1016\/j.bmcl.2008.04.034 (2008).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"19","key":"30652_CR60","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.4155\/fmc-2019-0181","volume":"11","author":"MR Bauer","year":"2019","unstructured":"Bauer, M. R. et al. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C. Future Med. Chem. 11(19), 2491\u20132504. https:\/\/doi.org\/10.4155\/fmc-2019-0181 (2019).","journal-title":"Future Med. Chem."},{"key":"30652_CR61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-7015-5_9","volume":"1611","author":"M Brylinski","year":"2017","unstructured":"Brylinski, M. Local alignment of ligand binding sites in proteins for polypharmacology and drug repositioning. Methods Mol. Biol. 1611, 109\u2013122. https:\/\/doi.org\/10.1007\/978-1-4939-7015-5_9 (2017).","journal-title":"Methods Mol. Biol."},{"key":"30652_CR62","doi-asserted-by":"publisher","first-page":"23605","DOI":"10.1038\/srep23605","volume":"6","author":"L Tian","year":"2016","unstructured":"Tian, L., Liu, S., Wang, S. & Wang, L. Ligand-binding specificity and promiscuity of the main lignocellulolytic enzyme families as revealed by active-site architecture analysis. Sci. Rep. 6, 23605. https:\/\/doi.org\/10.1038\/srep23605 (2016).","journal-title":"Sci. Rep."},{"key":"30652_CR63","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume":"1263","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 1263, 243\u2013250. https:\/\/doi.org\/10.1007\/978-1-4939-2269-7_19 (2015).","journal-title":"Methods Mol. Biol."},{"issue":"11","key":"30652_CR64","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2174\/1389203718666170622074741","volume":"18","author":"I Kumari","year":"2017","unstructured":"Kumari, I., Sandhu, P., Ahmed, M. & Akhter, Y. Molecular dynamics simulations, challenges and opportunities: A biologist\u2019s prospective. Curr. Protein Pept. Sci. 18(11), 1163\u20131179. https:\/\/doi.org\/10.2174\/1389203718666170622074741 (2017).","journal-title":"Curr. Protein Pept. Sci."},{"issue":"Pt 2","key":"30652_CR65","doi-asserted-by":"publisher","first-page":"129843","DOI":"10.1016\/j.ijbiomac.2024.129843","volume":"261","author":"Y Pan","year":"2024","unstructured":"Pan, Y., Zhao, C., Fu, W., Yang, S. & Lv, S. Comparative analysis of structural dynamics and allosteric mechanisms of RecA\/Rad51 family proteins: Integrated atomistic MD simulation and network-based analysis. Int. J. Biol. Macromol. 261(Pt 2), 129843. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129843 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"30652_CR66","doi-asserted-by":"publisher","first-page":"1395014","DOI":"10.3389\/fphar.2024.1395014","volume":"15","author":"M Saeed","year":"2024","unstructured":"Saeed, M., Haque, A., Shoaib, A. & Danish Rizvi, S. M. Exploring novel natural compound-based therapies for Duchenne muscular dystrophy management: Insights from network pharmacology, QSAR modeling, molecular dynamics, and free energy calculations. Front. Pharmacol. 15, 1395014. https:\/\/doi.org\/10.3389\/fphar.2024.1395014 (2024).","journal-title":"Front. Pharmacol."},{"key":"30652_CR67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s44371-024-00071-1","volume":"1","author":"ML Ali","year":"2024","unstructured":"Ali, M. L., Hoque, N., Hasan, M. M., Azme, E. & Noushin, F. Exploration of marine natural compounds as promising MDM2 inhibitors for treating triple-negative breast cancer: Insights from molecular docking, ADME\/T studies, molecular dynamics simulation and MM-PBSA binding free energy calculations. Discov. Chem. 1, 61. https:\/\/doi.org\/10.1007\/s44371-024-00071-1 (2024).","journal-title":"Discov. Chem."},{"issue":"36","key":"30652_CR68","doi-asserted-by":"publisher","first-page":"19073","DOI":"10.1021\/acs.langmuir.4c02154","volume":"40","author":"M Soroushmanesh","year":"2024","unstructured":"Soroushmanesh, M., Dinari, M. & Farrokhpour, H. Comprehensive computational investigation of the porphyrin-based COF as a nanocarrier for delivering anti-cancer drugs: A combined MD simulation and DFT calculation. Langmuir 40(36), 19073\u201319085. https:\/\/doi.org\/10.1021\/acs.langmuir.4c02154 (2024).","journal-title":"Langmuir"},{"issue":"7","key":"30652_CR69","doi-asserted-by":"publisher","first-page":"e0307501","DOI":"10.1371\/journal.pone.0307501","volume":"19","author":"M Khanal","year":"2024","unstructured":"Khanal, M. et al. Identification of potent inhibitors of HDAC2 from herbal products for the treatment of colon cancer: Molecular docking, molecular dynamics simulation, MM\/GBSA calculations, DFT studies, and pharmacokinetic analysis. PLoS ONE 19(7), e0307501. https:\/\/doi.org\/10.1371\/journal.pone.0307501 (2024).","journal-title":"PLoS ONE"},{"issue":"3","key":"30652_CR70","doi-asserted-by":"publisher","first-page":"e0299238","DOI":"10.1371\/journal.pone.0299238","volume":"19","author":"AKMM Huq","year":"2024","unstructured":"Huq, A. K. M. M. et al. Phenolic compounds of Theobroma cacao L. show potential against dengue RdRp protease enzyme inhibition by in-silico docking, DFT study, MD simulation and MMGBSA calculation. PLoS ONE 19(3), e0299238. https:\/\/doi.org\/10.1371\/journal.pone.0299238 (2024).","journal-title":"PLoS ONE"},{"key":"30652_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104455","volume":"134","author":"S Krishna","year":"2021","unstructured":"Krishna, S., Kumar, S. B., Murthy, T. K. & Murahari, M. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy. Comput. Biol. Med. 134, 104455. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104455 (2021).","journal-title":"Comput. Biol. Med."},{"issue":"14","key":"30652_CR72","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/08927022.2024.2376333","volume":"50","author":"S Kour","year":"2024","unstructured":"Kour, S. et al. Screening of DNMT3A inhibitors from phytochemicals using molecular docking and molecular dynamics simulation for their anti-cancer potential. Mol. Simul. 50(14), 1001\u20131018. https:\/\/doi.org\/10.1080\/08927022.2024.2376333 (2024).","journal-title":"Mol. Simul."},{"issue":"14","key":"30652_CR73","doi-asserted-by":"publisher","first-page":"7591","DOI":"10.1080\/07391102.2024.2313158","volume":"43","author":"M Priyadarshinee","year":"2024","unstructured":"Priyadarshinee, M. et al. Spectroscopic insights with molecular docking and molecular dynamic simulation studies of anticancer drug 5-Fluorouracil targeting human pyruvate kinase m2. J. Biomol. Struct. Dyn. 43(14), 7591\u20137603. https:\/\/doi.org\/10.1080\/07391102.2024.2313158 (2025).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"7","key":"30652_CR74","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1080\/07391102.2023.2220045","volume":"42","author":"P Nayana","year":"2024","unstructured":"Nayana, P. et al. A combined in vitro and molecular dynamics simulation studies unveil the molecular basis of the anticancer potential of piperine targeting AKT1 against prostate cancer. J. Biomol. Struct. Dyn. 42(7), 3616\u20133629. https:\/\/doi.org\/10.1080\/07391102.2023.2220045 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"30652_CR75","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00894-012-1661-3","volume":"19","author":"JF Franco-Gonzalez","year":"2013","unstructured":"Franco-Gonzalez, J. F., Cruz, V. L., Ramos, J. & Mart\u00ednez-Salazar, J. Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis. J. Mol. Model. 19(3), 1227\u20131236. https:\/\/doi.org\/10.1007\/s00894-012-1661-3 (2013).","journal-title":"J. Mol. Model."},{"issue":"6","key":"30652_CR76","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1080\/07391102.2023.2295385","volume":"43","author":"R Bhati","year":"2025","unstructured":"Bhati, R. et al. Molecular dynamics simulations assisted investigation of phytochemicals as potential lead candidates against anti-apoptotic Bcl-B protein. J. Biomol. Struct. Dyn. 43(6), 3049\u20133063. https:\/\/doi.org\/10.1080\/07391102.2023.2295385 (2025).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"30652_CR77","doi-asserted-by":"publisher","unstructured":"Das, R. P., Behera, S. K., Sahoo, B., Arakha, M. & Pradhan, A. K. Comparative analysis of backbone atom cross-correlation matrices and folding dynamics of amyloid fibril and its complexes with novel biosurfactants isolated from Bacillus strain: A binding free energy calculation (mM-PBSA) and MD simulation approach. J. Biomol. Struct. Dyn. Advance online publication, 1\u201316. https:\/\/doi.org\/10.1080\/07391102.2024.2446677 (2024).","DOI":"10.1080\/07391102.2024.2446677"},{"issue":"3","key":"30652_CR78","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s11030-021-10211-9","volume":"25","author":"B Gogoi","year":"2021","unstructured":"Gogoi, B. et al. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation. Mol. Divers. 25(3), 1963\u20131977. https:\/\/doi.org\/10.1007\/s11030-021-10211-9 (2021).","journal-title":"Mol. Divers."},{"key":"30652_CR79","doi-asserted-by":"publisher","first-page":"129245","DOI":"10.1016\/j.molstruc.2020.129245","volume":"1225","author":"DA Abdelrheem","year":"2021","unstructured":"Abdelrheem, D. A. et al. Isolation, characterization, in vitro anticancer activity, dft calculations, molecular docking, bioactivity score, drug-likeness and admet studies of eight phytoconstituents from brown alga Sargassum platycarpum. J. Mol. Struct. 1225, 129245. https:\/\/doi.org\/10.1016\/j.molstruc.2020.129245 (2021).","journal-title":"J. Mol. Struct."},{"key":"30652_CR80","doi-asserted-by":"publisher","first-page":"102755","DOI":"10.1016\/j.arr.2025.102755","volume":"108","author":"Y Liu","year":"2025","unstructured":"Liu, Y., Aquili, L., Wong, K. H., Lu, Z. & Lim, L. W. Past, present, and future of serotonin-targeting therapeutics for Alzheimer\u2019s disease: Perspectives from DNA methylation. Ageing Res. Rev. 108, 102755. https:\/\/doi.org\/10.1016\/j.arr.2025.102755 (2025).","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"30652_CR81","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1111\/ene.70017","volume":"32","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Apolipoprotein E epsilon4 allele is associated with better performance language and visual memory in spinocerebellar ataxia type 3. Eur. J. Neurol. 32(1), e70017. https:\/\/doi.org\/10.1111\/ene.70017 (2025).","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"30652_CR82","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/ijms26031325","volume":"26","author":"J Vieira","year":"2025","unstructured":"Vieira, J. et al. Predicting which mitophagy proteins are dysregulated in spinocerebellar ataxia type 3 (SCA3) using the auto-p2docking pipeline. Int. J. Mol. Sci. 26(3), 1325. https:\/\/doi.org\/10.3390\/ijms26031325 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"30652_CR83","doi-asserted-by":"publisher","first-page":"fcaf118","DOI":"10.1093\/braincomms\/fcaf118","volume":"7","author":"Y Huang","year":"2025","unstructured":"Huang, Y. et al. Beyond the cerebellum: Perivascular space burden in spinocerebellar ataxia type 3 extends to multiple brain regions. Brain Commun. 7(2), fcaf118. https:\/\/doi.org\/10.1093\/braincomms\/fcaf118 (2025).","journal-title":"Brain Commun."},{"key":"30652_CR84","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/j.jciso.2023.100096","volume":"12","author":"R Vaidyanathan","year":"2023","unstructured":"Vaidyanathan, R. et al. Molecular docking approach on the binding stability of derivatives of phenolic acids (DPAs) with human serum albumin (HSA): Hydrogen-bonding versus hydrophobic interactions or combined influences?\u00a0JCIS Open. 12, 100096. https:\/\/doi.org\/10.1016\/j.jciso.2023.100096 (2023).","journal-title":"JCIS Open."},{"key":"30652_CR85","doi-asserted-by":"publisher","first-page":"24504","DOI":"10.1038\/s41598-024-75527-6","volume":"14","author":"S Yadav","year":"2024","unstructured":"Yadav, S. et al. Investigate the binding of pesticides with the TLR4 receptor protein found in mammals and zebrafish using molecular docking and molecular dynamics simulations. Sci. Rep. 14, 24504. https:\/\/doi.org\/10.1038\/s41598-024-75527-6 (2024).","journal-title":"Sci. Rep."},{"issue":"3","key":"30652_CR86","doi-asserted-by":"publisher","first-page":"e0119264","DOI":"10.1371\/journal.pone.0119264","volume":"10","author":"L Mart\u00ednez","year":"2015","unstructured":"Mart\u00ednez, L. Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. PLoS ONE 10(3), e0119264. https:\/\/doi.org\/10.1371\/journal.pone.0119264 (2015).","journal-title":"PLoS ONE"},{"issue":"3","key":"30652_CR87","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/prot.22922","volume":"79","author":"A Bornot","year":"2011","unstructured":"Bornot, A., Etchebest, C. & de Brevern, A. G. Predicting protein flexibility through the prediction of local structures. Proteins 79(3), 839\u2013852. https:\/\/doi.org\/10.1002\/prot.22922 (2011).","journal-title":"Proteins"},{"issue":"16","key":"30652_CR88","doi-asserted-by":"publisher","first-page":"9722","DOI":"10.1021\/acs.chemrev.0c01195","volume":"121","author":"A Glielmo","year":"2021","unstructured":"Glielmo, A. et al. Unsupervised learning methods for molecular simulation data. Chem. Rev. 121(16), 9722\u20139758. https:\/\/doi.org\/10.1021\/acs.chemrev.0c01195 (2021).","journal-title":"Chem. Rev."},{"issue":"3","key":"30652_CR89","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10930-023-10113-9","volume":"42","author":"S Hayward","year":"2023","unstructured":"Hayward, S. A retrospective on the development of methods for the analysis of protein conformational ensembles. Protein J. 42(3), 181\u2013191. https:\/\/doi.org\/10.1007\/s10930-023-10113-9 (2023).","journal-title":"Protein J."},{"key":"30652_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109245","volume":"183","author":"S Moradi","year":"2024","unstructured":"Moradi, S. et al. A review on description dynamics and conformational changes of proteins using combination of principal component analysis and molecular dynamics simulation. Comput. Biol. Med. 183, 109245. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.109245 (2024).","journal-title":"Comput. Biol. Med."},{"issue":"Pt 2","key":"30652_CR91","doi-asserted-by":"publisher","first-page":"129167","DOI":"10.1016\/j.ijbiomac.2023.129167","volume":"259","author":"M Furkan","year":"2024","unstructured":"Furkan, M. et al. Identifying repurposed drugs as potential inhibitors of Apolipoprotein E: A bioinformatics approach to target complex diseases associated with lipid metabolism and neurodegeneration. Int. J. Biol. Macromol. 259(Pt 2), 129167. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.129167 (2024).","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"30652_CR92","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1080\/07391102.2023.2200490","volume":"42","author":"AK Srivastava","year":"2024","unstructured":"Srivastava, A. K. et al. Identification and mechanistic exploration of structural and conformational dynamics of NF-kB inhibitors: Rationale insights from in silico and in vitro studies. J. Biomol. Struct. Dyn. 42(3), 1485\u20131505. https:\/\/doi.org\/10.1080\/07391102.2023.2200490 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"30652_CR93","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1750-3639.1997.tb00894.x","volume":"7","author":"BT Koshy","year":"1997","unstructured":"Koshy, B. T. & Zoghbi, H. Y. The CAG\/polyglutamine tract diseases: Gene products and molecular pathogenesis. Brain Pathol. 7(3), 927\u2013942. https:\/\/doi.org\/10.1111\/j.1750-3639.1997.tb00894.x (1997).","journal-title":"Brain Pathol."},{"key":"30652_CR94","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1017\/erm.2024.10","volume":"26","author":"E Hern\u00e1ndez-Carralero","year":"2024","unstructured":"Hern\u00e1ndez-Carralero, E., Quinet, G. & Freire, R. ATXN3: A multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3. Expert Rev. Mol. Med. 26, e19. https:\/\/doi.org\/10.1017\/erm.2024.10 (2024).","journal-title":"Expert Rev. Mol. Med."},{"issue":"7","key":"30652_CR95","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.3390\/ijms25073984","volume":"25","author":"F Stahl","year":"2024","unstructured":"Stahl, F., Evert, B. O., Han, X., Breuer, P. & W\u00fcllner, U. Spinocerebellar ataxia type 3 pathophysiology-implications for translational research and clinical studies. Int. J. Mol. Sci. 25(7), 3984. https:\/\/doi.org\/10.3390\/ijms25073984 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"30652_CR96","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13041-020-00723-0","volume":"14","author":"AS Sowa","year":"2021","unstructured":"Sowa, A. S. et al. Neurodegenerative phosphoprotein signaling landscape in models of SCA3. Mol. Brain 14(1), 57. https:\/\/doi.org\/10.1186\/s13041-020-00723-0 (2021).","journal-title":"Mol. Brain"},{"issue":"7454","key":"30652_CR97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nature12204","volume":"498","author":"J Park","year":"2013","unstructured":"Park, J. et al. RAS\u2013MAPK\u2013MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 498(7454), 325\u2013331. https:\/\/doi.org\/10.1038\/nature12204 (2013).","journal-title":"Nature"},{"issue":"9","key":"30652_CR98","doi-asserted-by":"publisher","first-page":"e0204438","DOI":"10.1371\/journal.pone.0204438","volume":"13","author":"L Zeng","year":"2018","unstructured":"Zeng, L. et al. Loss of the spinocerebellar ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways. PLoS ONE 13(9), e0204438. https:\/\/doi.org\/10.1371\/journal.pone.0204438 (2018).","journal-title":"PLoS ONE"},{"key":"30652_CR99","doi-asserted-by":"publisher","first-page":"104697","DOI":"10.1016\/j.nbd.2019.104697","volume":"137","author":"NS Ashraf","year":"2020","unstructured":"Ashraf, N. S. et al. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the spinocerebellar ataxia type 3 disease protein. Neurobiol. Dis. 137, 104697. https:\/\/doi.org\/10.1016\/j.nbd.2019.104697 (2020).","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"30652_CR100","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22038\/IJBMS.2019.37821.8995","volume":"23","author":"A Veisi","year":"2020","unstructured":"Veisi, A. et al. Role of crocin in several cancer cell lines: An updated review. Iran. J. Basic Med. Sci. 23(1), 3\u201312. https:\/\/doi.org\/10.22038\/IJBMS.2019.37821.8995 (2020).","journal-title":"Iran. J. Basic Med. Sci."},{"key":"30652_CR101","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3389\/fphar.2020.00694","volume":"11","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Resveratrol: Multi-targets mechanism on neurodegenerative diseases based on network pharmacology. Front. Pharmacol. 11, 694. https:\/\/doi.org\/10.3389\/fphar.2020.00694 (2020).","journal-title":"Front. Pharmacol."},{"issue":"7","key":"30652_CR102","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/ijnp\/pyad030","volume":"26","author":"H Li","year":"2023","unstructured":"Li, H., Zhang, Z., Li, H., Pan, X. & Wang, Y. New insights into the roles of p53 in central nervous system diseases. Int. J. Neuropsychopharmacol. 26(7), 465\u2013473. https:\/\/doi.org\/10.1093\/ijnp\/pyad030 (2023).","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"11","key":"30652_CR103","doi-asserted-by":"publisher","first-page":"e2000733","DOI":"10.1371\/journal.pbio.2000733","volume":"14","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. The Machado-Joseph disease deubiquitinase ataxin-3 regulates the stability and apoptotic function of p53. PLoS Biol. 14(11), e2000733. https:\/\/doi.org\/10.1371\/journal.pbio.2000733 (2016).","journal-title":"PLoS Biol."},{"issue":"10","key":"30652_CR104","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1093\/brain\/awad128","volume":"146","author":"M Raposo","year":"2023","unstructured":"Raposo, M. et al. Blood transcriptome sequencing identifies biomarkers able to track disease stages in spinocerebellar ataxia type 3. Brain 146(10), 4132\u20134143. https:\/\/doi.org\/10.1093\/brain\/awad128 (2023).","journal-title":"Brain"},{"issue":"12","key":"30652_CR105","doi-asserted-by":"publisher","first-page":"e11801","DOI":"10.15252\/msb.202311801","volume":"19","author":"D Na","year":"2023","unstructured":"Na, D. et al. A multi-layered network model identifies Akt1 as a common modulator of neurodegeneration. Mol. Syst. Biol. 19(12), e11801. https:\/\/doi.org\/10.15252\/msb.202311801 (2023).","journal-title":"Mol. Syst. Biol."},{"key":"30652_CR106","unstructured":"Meglio, M. Troriluzole shows promise in spinocerebellar ataxia type 3 subgroup despite failing to achieve primary end point. NeurologyLive https:\/\/www.neurologylive.com\/view\/troriluzole-shows-promise-spinocerebellar-ataxia-type-3-subgroup-despite-failing-achieve-primary-end-point (2022)."},{"issue":"3","key":"30652_CR107","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.neuro.2009.02.014","volume":"30","author":"M Janahmadi","year":"2009","unstructured":"Janahmadi, M. et al. Co-treatment with riluzole, a neuroprotective drug, ameliorates the 3-acetylpyridine-induced neurotoxicity in cerebellar Purkinje neurones of rats: Behavioural and electrophysiological evidence. Neurotoxicology 30(3), 393\u2013402. https:\/\/doi.org\/10.1016\/j.neuro.2009.02.014 (2009).","journal-title":"Neurotoxicology"},{"issue":"4","key":"30652_CR108","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s13311-020-00941-3","volume":"17","author":"SL Perlman","year":"2020","unstructured":"Perlman, S. L. Update on the treatment of ataxia: Medication and emerging therapies. Neurotherapeutics 17(4), 1660\u20131664. https:\/\/doi.org\/10.1007\/s13311-020-00941-3 (2020).","journal-title":"Neurotherapeutics"},{"issue":"7 Supplement 1","key":"30652_CR109","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1212\/WNL.0000000000205167","volume":"102","author":"M Beiner","year":"2024","unstructured":"Beiner, M. et al. Matching-adjusted indirect comparison of troriluzole versus untreated natural history cohort in spinocerebellar ataxia (S35. 009). Neurology 102(7 Supplement 1), 3472. https:\/\/doi.org\/10.1212\/WNL.0000000000205167 (2024).","journal-title":"Neurology"},{"issue":"6","key":"30652_CR110","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1007\/s11030-025-11132-7","volume":"9","author":"BH Kumar","year":"2025","unstructured":"Kumar, B. H., Kabekkodu, S. P. & Pai, K. S. R. Structural insights of AKT and its activation mechanism for drug development. Mol. Divers. 9(6), 5443\u20135463. https:\/\/doi.org\/10.1007\/s11030-025-11132-7 (2025).","journal-title":"Mol. Divers."},{"issue":"5170","key":"30652_CR111","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.8023157","volume":"265","author":"Y Cho","year":"1994","unstructured":"Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265(5170), 346\u2013355. https:\/\/doi.org\/10.1126\/science.8023157 (1994).","journal-title":"Science"},{"key":"30652_CR112","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1146\/annurev.biochem.77.060806.091238","volume":"77","author":"AC Joerger","year":"2008","unstructured":"Joerger, A. C. & Fersht, A. R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557\u2013582. https:\/\/doi.org\/10.1146\/annurev.biochem.77.060806.091238 (2008).","journal-title":"Annu. Rev. Biochem."},{"issue":"24","key":"30652_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/lcm-22-4","volume":"5","author":"S Soeda","year":"2022","unstructured":"Soeda, S., Ohta, T., Uto, T. & Shoyama, Y. The effect of crocin on neuroprotective activity in vitro: A narrative review. Longhua Chin. Med. 5(24), 1\u201312. https:\/\/doi.org\/10.21037\/lcm-22-4 (2022).","journal-title":"Longhua Chin. Med."},{"issue":"2","key":"30652_CR114","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3892\/ijmm.2018.4032","volume":"43","author":"C Wang","year":"2019","unstructured":"Wang, C. et al. Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer\u2019s disease. Int. J. Mol. Med. 43(2), 956\u2013966. https:\/\/doi.org\/10.3892\/ijmm.2018.4032 (2019).","journal-title":"Int. J. Mol. Med."},{"key":"30652_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.757729","volume":"13","author":"K Zhong","year":"2022","unstructured":"Zhong, K. et al. Anti-epileptic effect of crocin on experimental temporal lobe epilepsy in mice. Front. Pharmacol. 13, 757729. https:\/\/doi.org\/10.3389\/fphar.2022.757729 (2022).","journal-title":"Front. Pharmacol."},{"issue":"11","key":"30652_CR116","first-page":"895","volume":"17","author":"JR Sarshoori","year":"2014","unstructured":"Sarshoori, J. R., Asadi, M. H. & Mohammadi, M. T. Neuroprotective effects of crocin on the histopathological alterations following brain ischemia-reperfusion injury in rat. Iran. J. Basic Med. Sci. 17(11), 895\u2013902 (2014).","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"1","key":"30652_CR117","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1515\/biol-2022-0468","volume":"17","author":"A Daneshvar","year":"2022","unstructured":"Daneshvar, A. et al. Neuroprotective effects of crocin and crocin-loaded niosomes against the paraquat-induced oxidative brain damage in rats. Open Life Sci. 17(1), 1174\u20131181. https:\/\/doi.org\/10.1515\/biol-2022-0468 (2022).","journal-title":"Open Life Sci."},{"issue":"2","key":"30652_CR118","doi-asserted-by":"publisher","first-page":"745","DOI":"10.22037\/ijpr.2019.2393","volume":"18","author":"S Mozaffari","year":"2019","unstructured":"Mozaffari, S.,Yasuj, S.R., Motaghinejad, M., Motevalian, M. & Kheiri, R. Crocin acting as a neuroprotective agent against methamphetamine-induced neurodegeneration via CREB-BDNF signaling pathway. Iran. J. Pharm. Res. : IJPR 18(2),\u00a0745\u2013758. https:\/\/doi.org\/10.22037\/ijpr.2019.2393 (2019).","journal-title":"Iran. J. Pharm. Res. : IJPR"},{"issue":"5","key":"30652_CR119","doi-asserted-by":"publisher","first-page":"e3503","DOI":"10.1002\/brb3.3503","volume":"14","author":"W Su","year":"2024","unstructured":"Su, W., Wang, Y., Shao, S. & Ye, X. Crocin ameliorates neuroinflammation and cognitive impairment in mice with Alzheimer\u2019s disease by activating PI3K\/AKT pathway. Brain Behav. 14(5), e3503. https:\/\/doi.org\/10.1002\/brb3.3503 (2024).","journal-title":"Brain Behav."},{"issue":"1","key":"30652_CR120","first-page":"1","volume":"7","author":"T Farkhondeh","year":"2018","unstructured":"Farkhondeh, T., Samarghandian, S., Yazdi, H. S. & Samini, F. The protective effects of crocin in the management of neurodegenerative diseases: A review. Am. J. Neurodegener Dis. 7(1), 1\u201310 (2018).","journal-title":"Am. J. Neurodegener Dis."},{"key":"30652_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.863089","volume":"10","author":"K Jansen-West","year":"2022","unstructured":"Jansen-West, K. et al. Plasma polyQ-ATXN3 levels associate with cerebellar degeneration and behavioral abnormalities in a new AAV-based SCA3 mouse model. Front. Cell Dev. Biol. 10, 863089. https:\/\/doi.org\/10.3389\/fcell.2022.863089 (2022).","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"30652_CR122","doi-asserted-by":"publisher","first-page":"CD001447","DOI":"10.1002\/14651858.CD001447.pub3","volume":"2012","author":"RG Miller","year":"2012","unstructured":"Miller, R. G., Mitchell J. D. & Moore, D. H. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst. Rev.\u00a02012(3), CD001447. https:\/\/doi.org\/10.1002\/14651858.CD001447.pub3 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"30652_CR123","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"K Abe","year":"2017","unstructured":"Abe, K. et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16(7), 505\u2013512. https:\/\/doi.org\/10.1016\/S1474-4422(17)30115-1 (2017).","journal-title":"Lancet Neurol."},{"issue":"1","key":"30652_CR124","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003495-200161010-00005","volume":"61","author":"J Grutzendler","year":"2001","unstructured":"Grutzendler, J. & Morris, J. C. Cholinesterase inhibitors for Alzheimer\u2019s disease. Drugs 61(1), 41\u201352. https:\/\/doi.org\/10.2165\/00003495-200161010-00005 (2001).","journal-title":"Drugs"},{"issue":"11","key":"30652_CR125","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s11064-020-03134-8","volume":"45","author":"S Kermanshahi","year":"2020","unstructured":"Kermanshahi, S. et al. Novel neuroprotective potential of crocin in neurodegenerative disorders: An illustrated mechanistic review. Neurochem. Res. 45(11), 2573\u20132585. https:\/\/doi.org\/10.1007\/s11064-020-03134-8 (2020).","journal-title":"Neurochem. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30652-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:34:25Z","timestamp":1771590865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30652-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30652"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30652-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7332"}}